Nestlé and EraCal enter into strategic partnership

20 February 2023 08:58

Zurich CCGreater ZurichGreater Geneva Bern

Schlieren/Vevey - Nestlé is joining forces with the biotech firm EraCal Therapeutics from the Greater Zurich Area. The partners will seek to develop new compounds to facilitate controlled food intake. This would be of benefit to metabolic disease patients.

The food giant Nestlé from Western Switzerland has concluded an agreement centered on a research partnership with EraCal Therapeutics, a biotech firm from Schlieren in the canton of Zurich. Together, the partners intend to identify new nutraceuticals to control food intake, further details of which can be found in a press release. Nutraceuticals are understood to mean foods or parts of a food that offer a medicinal benefit.

Via its subsidiary Nestlé Health Science, Nestlé will bring resources in the area of nutraceutical compounds to the table within the framework of the partnership. EraCal Therapeutics will make its drug development platform available. This should help with the identification of relevant compounds, among other aspects.

According to the information presented in the press release, the nutraceuticals identified within the framework of this partnership should be of benefit to people with metabolic diseases. Hans-Jürgen Woerle, Chief Scientific and Medical Officer of Nestlé Health Science, explains that metabolic health is a key area of interest for the multinational food and drink processing conglomerate.

EraCal Therapeutics was founded as a spin-off from the University of Zurich and Harvard University in the USA. The company is also working on the development of an appetite suppressant itself. ssp

Swiss Pavilion Digital

Previous newsletters